Biogazelle, a CellCarta company, offers expert laboratory services (some of which under ISO 17025 accreditation or GCLP compliancy) in the area of transcriptome and genomic analysis. To this purpose, various nucleic acid quantification methods such as RNA sequencing, quantitative PCR and digital PCR are being used, supported by unique software tools for data-analysis. State-of-the-art RNA sequencing workflows are optimized for quantification of coding and non-coding (small RNA and long non-coding RNA) genes in all type of clinically relevant samples, including FFPE tissue and body fluids, with minimal input requirements. Beyond gene expression level analysis, Biogazelle also performs RNA variant identification (e.g. mutations and fusion genes), and has established an RNA biomarker development program offering an end-to-end solution from RNA biomarker panel discovery to the development of a PCR-based molecular diagnostic test. Our proprietary RNA biomarker discovery platform covers the entire workflow from study design, data generation to identification of RNA biomarkers. Advanced data mining methods are applied to identify robust biomarker signatures that are further developed into a PCR-based biomarker assay (e.g. LDT, CE-IVD, CDx) Of note, Biogazelle also serves as a specialty lab in the field of clinical trials or in routine diagnostic settings. If you need a lab with internationally recognized and accredited expertise in RT-qPCR or digital PCR for running your clinical samples, for example using a test that we developed in a previous phase for you, Biogazelle can support you perfectly well.